AACC uses cookies to ensure the best website experience. Continuing without changing cookie settings assumes you consent to our use of cookies on this device. You can change these settings at any time, but that may impair functionality on our websites. Review our cookie and privacy policy

Poster Abstracts

28th ADLM International CPOCT Symposium

The call for poster abstracts submissions is now closed for the upcoming meeting. Poster abstract submitters will be notified by email of decisions by early August. Please note, the presenting author (e.g., poster abstract submitter) must be registered for the meeting to present their poster. Please also note that the early registration deadline.

All submitted abstracts will be reviewed for clarity, scientific impact, and integrity. Abstract submissions must be relevant to the topics within critical and point-of-care testing. Submitters of the top poster abstract submissions will be invited to present their work as a 15-minute oral presentation to an audience of thought-leaders and peers in addition to displaying their poster(s) during the meeting. All accepted posters will be published as a supplement in the Association for Diagnostics & Laboratory Medicine’s (formerly AACC) online peer-reviewed publication, The Journal of Applied Laboratory Medicine (JALM). Additional details on poster preparation will be provided after notices are sent in early August.

Please contact [email protected] with any poster abstract questions.

Key Dates and Deadline

  • Call for poster abstract submissions closed July 18, 2022.
  • 28th the Association for Diagnostics & Laboratory Medicine (ADLM) International CPOCT Symposium will be held September 21 – 23, 2022.

List of Accepted Scientific Poster Abstracts

Poster presentations will be on display starting Wednesday, September 21, at 5:30 p.m. Poster displays conclude at the end of the conference on Friday, September 23, at 5:00 p.m.

  1. Real-Time, Multiplexed CRISPR-Cas Diagnostics to Enable Point-of-Need In Vitro Diagnostic Testing
    Elizabeth Fiore, Sherlock Biosciences, Inc., Watertown, MA (United States)
  2. Selection of DNA Aptamers for Point-of-Care Detection
    Juewen Liu, University of Waterloo, Waterloo, ON (Canada)
  3. Verification Studies of New Point-of-Care Testing CBC Analyzer (Sight OLO) for Use in Rural and Remote Health Centers in the Province of Newfoundland and Labrador, Canada
    Vinita Thakur, Department of Laboratory Medicine, Health Sciences Center, Eastern health Authority and Memorial University, St John's, NL (Canada)
  4. Improving COVID-19 Antibody Detection in Breastmilk Using Commercially Available COVID-19 Lateral Flow Strip Assays
    Brenda Torres, CanaryQ, Mountain View, CA (United States)
  5. Filtering Fingerstick-Blood Can Help Reduce the Overestimate of Glucose Levels in Anemic Samples
    Brenda Torres, CanaryQ, Mountain View, CA (United States)
  6. Glucose Readings from Filtered Fingerstick Plasma Remain Constant Across 4 Hours at Room Temperature: Ideal for Oral Glucose Tolerance Testing
    Brenda Torres, CanaryQ, Mountain View, CA (United States)
  7. Innovative Artificial Intelligence Driven Antibody Test for Point-of-Care
    Rian Wendling, NanoSpot.ai, Inc., Salt Lake City, UT (United States)
  8. Establishing Quality Indicators for Point-of-Care Testing
    Julie Shaw, Eastern Ontario Regional Laboratories Association/University of Ottawa, Ottawa, ON (Canada)
  9. SARS-CoV-2 Result Positivity Rates Tracked Over Time in Symptomatic and Asymptomatic Individuals Tested with Molecular and Rapid Antigen Testing Methods
    Raed Sulaiman, Avera McKennan Hospital and University Health Center, Sioux Falls, SD (United States)
  10. Analytical Performance of the Visby Sexual Health Point-of-Care Test for Sexually Transmitted Infections
    Leslie Donato, Mayo Clinic, Rochester, MN (United States)
  11. Point-of-Care Testing in Philippine Ground Ambulances, a Sea Ambulance, and Emergency Rescue Vehicles
    Anna Fuezery, Alberta Precision Laboratories, Edmonton, AB (Canada)
  12. Analytical Verification and Clinical Deployment of the Nova StatStrip Xpress Glucose Meter in Ground Ambulances
    Anna Fuezery, Alberta Precision Laboratories, Edmonton, AB (Canada)
  13. Analytical Performance Verification and Quality Assurance Program Changes for Point-of-Care ROTEM Thromboelastometry in Cardiovascular Surgery
    Anna Fuezery, Alberta Precision Laboratories, Edmonton, AB (Canada)
  14. A Study of Peritoneal Lactate Levels in Emergency Abdominal Pain Evaluation: Role of Point-of-Care Testing in Emergency Settings
    Shilpa Hasija, ESIC-PGIMSR, Delhi, Delhi (India)
  15. Diagnostic performance of regulatory approved rapid antigen point-of-care tests in the Omicron BA.4/BA.5 era in South Africa
    Vidya Keshav, Wits Diagnostic Innovation Hub, University of the Witwatersrand, Johannesburg (South Africa)
  16. Impact of a Point-of-Care Test for Chlamydia Trachomatis (CT), Neisseria Gonorrhoeae (NG), and Trichomonas Vaginalis (TV) On Patient Care in an Urgent Care Clinic
    Teresa Abraham, Visby Medical, San Jose, CA (United States)
  17. Nanofluidic Technology Enables Rapid Quantification of Pancreatic Stone Protein as an Early Biomarker of Sepsis: Method Comparison of the abioSCOPE In-Vitro Diagnostic Device
    Romy Benninga, Abionic, Cambridge, MA (United States)
  18. Validation of a Novel 2-Minute IVD COVID-19 Rapid Antigen Test on the AbioSCOPE® Device for Detection of SARS-CoV-2 Through Nanofluidics
    Romy Benninga, Abionic SA, Epalinges (Switzerland)
  19. Performance Evaluation of Nova Century Scientific One Step Multi-Line Screen Test Device for Measurement of Drugs of Abuse in the Urine
    Yury Butorin, Alberta Precision Laboratories, Red Deer, AB (Canada)
  20. Procalcitonin as a Predictor of Early Sepsis in Cardiovascular Surgery with Cardiopulmonary Bypass
    Eilysh Hildebrand, Response Biomedical Corp., Vancouver, BC (Canada)
  21. Analytical Sensitivity of ACON and LumiraDx SARS-CoV-2 Rapid Antigen Tests for Detection of Presumed Omicron Variant
    Brad Karon, Mayo Clinic, Rochester, MN (United States)
  22. ProSpectral™: Fast, Accurate, and High-Throughput Screening of COVID-19 Infections
    Matt Keener, Pattern Computer, Inc., Friday Harbor, WA (United States)
  23. Evaluation of the Rapid Quidel Sofia 2 Lyme Immunoassay as a First-Tier Test in a Two-Tier Testing Algorithm for Lyme Disease
    Kent Lewandrowski, Massachusetts general Hospital, Boston, MA (United States)
  24. Clinical Evaluation of a New, Near-Patient Testing (NPT) IL-6 Assay to Identify the Disease Severity in COVID-19 Patients
    Madhusudhanan Narasimhan, UT Southwestern Medical Center, Dallas, TX (United States)
  25. Contamination of Glucose Test Strips with Hand Sanitizer or Cleaning Solution Leads to Erroneously Low Glucose Results
    Heather Paul, Alberta Precision Laboratories/University of Calgary, Calgary, AB (Canada)
  26. A Rapid, Cell-Free Test for the Quantitative Measurement of Neutralizing Antibody Activity Against SARS-CoV-2 and Its Variants
    Alexandra Perebikovsky, Autonomous Medical Devices Inc, Santa Ana, CA (United States)
  27. An Optimal Extraction Method for STI Organisms for Microfluidic Application
    Cheryl Sesler, Eurofins ARCA Technology, Inc., Huntsville, AL (United States)
  28. Point-of-Care 13 C-Urea Breath Test Implementation in the Endoscopy Unit at King Faisal Specialist Hospital and Research Centre
    Mohamed Abdelsalam, King Faisal Specialist Hospital and Research Centre, Riyadh (Saudi Arabia)
  29. Evidence Based Approach to Implementing Point-of-Care Testing Methods and Practices in the Philippines
    Merlito De Torres, Sidra Medicine, Doha (Qatar)
  30. Quality Control, Cost Efficiency, and Improving Turnaround Time Using Individualized Quality Control Program in Point-of-Care Testing and Main Laboratory Setup
    Muhammad Durrani, SBH, Bronx, NY (United States)
  31. Prevalence of Hemolyzed Whole Blood Potassium Results in Acute Care Settings
    James Nichols, Vanderbilt University Medical Center, Nashville, TN (United States)
  32. Implementation of a Standardized Communication and Process for Preventing Loss of Glucose Meters and Patient Results
    Shivani Sharma, Trillium Health Partners, Mississauga, ON (Canada)
  33. Comparison of the eGFR Calculated Using Whole Blood Creatinine Measured with Radiometer ABL 827 FLEX with the eGFR Calculated Using Plasma Creatinine
    Lu Song, University of California, Los Angeles, Los Angeles, CA (United States)
  34. Potential Application of Point-of-Care Glucose and Beta-Hydroxybutyrate Measurements for Suspected Diabetic Ketoacidosis on Decedent Blood and Vitreous Humor in Forensic Autopsy
    Paul Yip, Sunnybrook Hospital and University of Toronto, Toronto, ON (Canada)

Poster Preparation Guidelines & Requirements


Presenting authors are required to register as a conference attendee. Please note, any requests to change the presenting author must be made in writing to [email protected] by August 10 for consideration. Poster abstracts will not be included in program materials or JALM supplement until registration of the presenting author is confirmed..


If you plan to withdraw your abstract, please notify [email protected] in writing as soon as possible including the abstract title and author name.


ADLM does not provide poster printing services. It is the responsibility of poster presenters to prepare and print their poster(s) for display on the provided poster boards. Please review the size and space information carefully as you prepare your poster.

  • The maximum size for an accepted poster is 46 inches (117 cm) x 46 inches (117 cm). If your poster exceeds the limit, it may be cut, folded, or otherwise modified to permit the allotted display room.
  • The poster abstract number provided by ADLM will be placed in the upper corner and measures 8.5 inches wide by 5.5 inches high (approximately 22 cm x 14 cm).
  • Due to social distancing, you will not share the poster board with another poster.


Each accepted poster must contain the following information:

  • Title as submitted in your abstract submission.
  • Presenting author and all co-authors.
  • Author(s) affiliation(s).
  • Background of your study (why you did this work).
  • Method(s) used to achieve a solution.
  • Results obtained (figures, tables, etc.).
  • Conclusions and importance of your work to laboratory medicine.

Please note that ADLM only provides the poster abstract number placed in the upper corner. It is the responsibility of the poster presenter to print and display their poster(s) at the designated times.


  • The information you display should have a professional appearance.
  • Instruments, components, and reagents are NOT permitted in the poster area.
  • All information should be easily read from at least 5 feet away from your poster.
    • Headings for abstract title and numbering for subsections should be a minimum of 72 pt font (approximately 1 inch or 2.5 cm height).
    • Subheadings should be a minimum of 36 pt font (approximately 0.5 inches or 1 cm height).
    • All type should be a minimum of 24 pt font (approximately 0.3 inches or 0.8 cm height) and readable from a distance of 5-7 feet (1.5-1.7 meters).


  • Instruments, components, or reagents are NOT permitted in the poster area.


You are required to set up your poster between 5 – 5:30 p.m. on Wednesday, September 21, 2022. Please collect your badge at the registration table and identify your poster number for your spot at the poster presentation section.

Your poster is to remain on display for the entire duration of the conference and removed Friday, September 23, 2022 by 5:30 p.m.

ADLM is not responsible for posters left on boards after the conference concludes.